Literature DB >> 15342469

Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract.

Hiroshi Iwata1, Yasuhiro Tezuka, Shigetoshi Kadota, Akira Hiratsuka, Tadashi Watabe.   

Abstract

Schisandra fruit, a Schisandraceae family herb, is used as a component in Kampo medicines (developed from Chinese medicines, but established in Japan). It can act as a sedative and antitussive, improve hepatic function, and give a general tonic effect. An extract of Schisandra fruit has been shown with a potent inhibitory effect on human liver microsomal erythromycin N-demethylation activity mediated by cytochrome P450 3A4 (CYP3A4). The present study was conducted to identify Schisandra fruit components having inhibitory effects on CYP3A4 by surveying the effect on human liver microsomal erythromycin N-demethylation activity. Known components of Schisandra fruit, gomisins B, C, G, and N and gamma-shizandrin, showed inhibitory effects on N-demethylation activity. Among these components, gomisin C displayed the most potent and competitive inhibitory effect, with a Ki value of 0.049 microM. Furthermore, the inhibitory effect of gomisin C was stronger than that of ketoconazole (Ki = 0.070 microM), a known potent CYP3A4 inhibitor. Gomisin C, however, inhibited CYP1A2-, CYP2C9-, CYP2C19-, and CYP2D6-dependent activities only to a limited extent (IC50 values >10 microM). Moreover, gomisin C inactivated human liver microsomal erythromycin N-demethylation activity in a time- and concentration-dependent manner. The inactivation kinetic parameters k(inact) and K(I) were 0.092 min(-1) and 0.399 microM, respectively. The human liver microsomal erythromycin N-demethylation activity inactivated by gomisin C did not recover on dialysis of the microsomes. Spectral scanning of CYP3A4 with gomisin C yielded an absorbance at 455 nm, suggesting that gomisin C inactivated the cytochrome P450 via the formation of a metabolite intermediate complex. This pattern is consistent with the metabolism of the methylenedioxy substituent in gomisin C. These results indicate that gomisin C is a mechanism-based inhibitor that not only competitively inhibits but irreversibly inactivates CYP3A4.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15342469     DOI: 10.1124/dmd.104.000646

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  23 in total

1.  The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6.

Authors:  Masashi Nakao; Yousuke Muramoto; Motoko Hisadome; Naoko Yamano; Mami Shoji; Yumi Fukushima; Junji Saruwatari; Kazuko Nakagawa
Journal:  Eur J Clin Pharmacol       Date:  2007-02-13       Impact factor: 2.953

2.  Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers.

Authors:  Hua-Wen Xin; Xiao-Chun Wu; Qing Li; Ai-Rong Yu; Min Zhu; Yang Shen; Dan Su; Lei Xiong
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

3.  Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers.

Authors:  Hua-Wen Xin; Xiao-Chun Wu; Qing Li; Ai-Rong Yu; Lei Xiong
Journal:  Br J Clin Pharmacol       Date:  2009-02-04       Impact factor: 4.335

4.  Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration.

Authors:  Yiming Jiang; Xiaomei Fan; Ying Wang; Pan Chen; Hang Zeng; Huasen Tan; Frank J Gonzalez; Min Huang; Huichang Bi
Journal:  Toxicol Sci       Date:  2014-10-14       Impact factor: 4.849

5.  Co-administration of Wuzhi capsules and tacrolimus in patients with idiopathic membranous nephropathy: clinical efficacy and pharmacoeconomics.

Authors:  Zhanfeng Sun; Miaomiao Ren; Qiong Wu; Xuanyi Du
Journal:  Int Urol Nephrol       Date:  2014-08-22       Impact factor: 2.370

6.  Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

Authors:  Michael Mohutsky; Stephen D Hall
Journal:  Methods Mol Biol       Date:  2021

7.  Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2020-05-13       Impact factor: 4.335

8.  Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6(*)1 and CYP2D6(*)10 using cell-based models in vitro.

Authors:  Qiang Qu; Jian Qu; Lu Han; Min Zhan; Lan-xiang Wu; Yi-wen Zhang; Wei Zhang; Hong-hao Zhou
Journal:  Acta Pharmacol Sin       Date:  2014-05       Impact factor: 6.150

Review 9.  "Natural" is not synonymous with "Safe": Toxicity of natural products alone and in combination with pharmaceutical agents.

Authors:  Tyler E Gaston; Donna L Mendrick; Mary F Paine; Amy L Roe; Catherine K Yeung
Journal:  Regul Toxicol Pharmacol       Date:  2020-03-18       Impact factor: 3.271

10.  Wuzhi tablet (Schisandra Sphenanthera extract) protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of NRF2-ARE and p53/p21 pathways.

Authors:  Xiaomei Fan; Yiming Jiang; Ying Wang; Huasen Tan; Hang Zeng; Yongtao Wang; Pan Chen; Aijuan Qu; Frank J Gonzalez; Min Huang; Huichang Bi
Journal:  Drug Metab Dispos       Date:  2014-09-12       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.